Reset Pharmaceuticals, Inc., corporate

Reset Pharmaceuticals, Inc.,

05.01.2023 - 14:03:45

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

said, ?We believe Innes? successful track record in commercializing multiple CNS drugs will lend itself well as our industry continues to evaluate what the economic model around psychedelic-assisted psychotherapy will be. Psilocybin, combined with psychotherapy, holds great promise to alleviate the mental suffering for millions of patients with cancer and other life-threatening illnesses. The research of trailblazers in the field has inspired so many of us to seek to get these therapies approved and available to those in need. We?re thrilled to have Innes on board at Reset Pharma to help make this a reality.?

Innes Meldrum, President and Chief Executive Officer, commented, ?I am excited to join Reset Pharma as the Company accelerates its progress and look forward to working with the team to advance our programs, including psilocybin-related therapy for cancer patients with demoralization syndrome and other mental health conditions.?

Up to 40% of all cancer patients in the US, representing almost seven million individuals, may be diagnosed with a mood disorder. An estimated 20% of all patients with life-altering cancer have clinically relevant demoralization that often occurs independent of other mood disorders like depression or anxiety. These patients have symptoms, such as hopelessness, helplessness and discouragement, which are associated with a loss of confidence in one?s ability to cope with significant distress. They are also more likely to have suicidal thoughts, have more difficulties with adherence to cancer therapy, and lack effective treatment options.[2] [3] [4]

About Reset Pharmaceuticals, Inc.

Reset Pharma is a privately held, US-based biotechnology company developing and commercializing novel clinical-stage treatments for patients suffering from mental illness related to life-altering diseases. The Company?s lead program initially focuses on developing a psilocybin-related product to treat Demoralization Syndrome in patients with cancer. These patients have clinically relevant levels of demoralization with a perceived lack of control, hopelessness and helplessness and an increased risk of suicide. While the primary focus is the development of a psilocybin-related product for demoralization, as there are currently no effective treatments for this disorder, psilocybin also shows promise as a treatment for anxiety and depression in cancer patients. Reset Pharma has established a highly experienced biotech development team with a strong track record of successful approvals and launches of neuroscience drugs in the US. The Company also has a Scientific Advisory Board of key opinion leaders in psychiatry, oncology and psychedelics, as well as a Strategic Advisory Board. Information about Reset Pharma can be found at

Forward-Looking Statements

This press release contains ?forward-looking statements? concerning the development and commercialization of Reset Pharmaceuticals? products, timing of clinical trials, the Company?s business development efforts and its expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements, including the ability to obtain funding to support planned clinical activities. These statements are made as of the date of this press release. Actual results may vary. Reset Pharmaceuticals undertakes no obligation to update any forward-looking statements for any reason.

For further information please contact:

Reset Pharmaceuticals, Inc.


Media inquiries:

MC Services AG Laurie


[1] Abilify Maintena? is a registered trademark of 343?50[3] Watson et al, European Journal of Cancer 2005; 41: 1710?1714[4] Vehling et al, Cancer 2017;123:3394-401.

05.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at